Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23209287 | 0.91 | JAK2 (0.42) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31318293 | 0.88 | JAK2 (0.39) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL25226197 | 0.88 | JAK2 (0.43) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423897 | 0.85 | JAK2 (0.40) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423956 | 0.84 | JAK2 (0.46) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423977 | 0.84 | JAK2 (0.37) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL31318298 | 0.83 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31318294 | 0.83 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209411 | 0.82 | JAK2 (0.44) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL23209356 | 0.82 | JAK2 (0.43) | JAK2JAK1TYK2JAK3MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415840-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415840-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | JAK2 232/4885JAK1 605/4885TYK2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.